Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,977,499
  • Shares Outstanding, K 68,464
  • Annual Sales, $ 43,950 K
  • Annual Income, $ -154,940 K
  • EBIT $ -231 M
  • EBITDA $ -228 M
  • 60-Month Beta 1.12
  • Price/Sales 68.97
  • Price/Cash Flow N/A
  • Price/Book 4.31

Options Overview Details

View History
  • Implied Volatility 56.34% ( -9.26%)
  • Historical Volatility 35.36%
  • IV Percentile 39%
  • IV Rank 13.80%
  • IV High 147.11% on 05/16/24
  • IV Low 41.81% on 11/27/23
  • Put/Call Vol Ratio 0.33
  • Today's Volume 4
  • Volume Avg (30-Day) 213
  • Put/Call OI Ratio 1.31
  • Today's Open Interest 9,038
  • Open Int (30-Day) 8,108

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.00
  • Number of Estimates 8
  • High Estimate -0.81
  • Low Estimate -1.37
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +8.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.30 +1.49%
on 11/20/24
55.39 -22.50%
on 11/07/24
-9.76 (-18.52%)
since 10/18/24
3-Month
42.30 +1.49%
on 11/20/24
55.39 -22.50%
on 11/07/24
-10.78 (-20.07%)
since 08/20/24
52-Week
22.26 +92.86%
on 11/27/23
61.61 -30.32%
on 05/24/24
+18.63 (+76.67%)
since 11/20/23

Most Recent Stories

More News
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

ONCY : 0.9985 (-5.80%)
HALO : 45.76 (+2.12%)
CADL : 3.98 (-0.25%)
MRUS : 42.93 (-1.29%)
RHHBY : 35.1300 (-0.79%)
ONC.TO : 1.40 (-5.41%)
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the...

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
RHHBY : 35.1300 (-0.79%)
HALO : 45.76 (+2.12%)
CADL : 3.98 (-0.25%)
MRUS : 42.93 (-1.29%)
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 0.9985 (-5.80%)
CADL : 3.98 (-0.25%)
AZN : 63.20 (-0.94%)
MRUS : 42.93 (-1.29%)
LTRN : 2.94 (-4.55%)
ONC.TO : 1.40 (-5.41%)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
CADL : 3.98 (-0.25%)
AZN : 63.20 (-0.94%)
MRUS : 42.93 (-1.29%)
LTRN : 2.94 (-4.55%)
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
RHHBY : 35.1300 (-0.79%)
MRUS : 42.93 (-1.29%)
MGNX : 3.28 (-5.75%)
IMRX : 2.04 (unch)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
PYXS : 3.82 (-8.17%)
AZN : 63.20 (-0.94%)
LLY : 753.41 (+3.25%)
MRUS : 42.93 (-1.29%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.40 (-5.41%)
ONCY : 0.9985 (-5.80%)
PYXS : 3.82 (-8.17%)
AZN : 63.20 (-0.94%)
LLY : 753.41 (+3.25%)
MRUS : 42.93 (-1.29%)
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
PYXS : 3.82 (-8.17%)
AZN : 63.20 (-0.94%)
LLY : 753.41 (+3.25%)
MRUS : 42.93 (-1.29%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

/PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in...

ONC.TO : 1.40 (-5.41%)
ONCY : 0.9985 (-5.80%)
MRUS : 42.93 (-1.29%)
GH : 30.68 (unch)
MDT : 84.11 (-1.05%)
NVDA : 145.89 (-0.76%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 26, 2023 – USA News Group  –  The seriousness of pancreatic cancer continues to grow, with increasing alarm since...

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
MRUS : 42.93 (-1.29%)
GH : 30.68 (unch)
MDT : 84.11 (-1.05%)
NVDA : 145.89 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

3rd Resistance Point 44.75
2nd Resistance Point 44.14
1st Resistance Point 43.53
Last Price 42.93
1st Support Level 42.31
2nd Support Level 41.70
3rd Support Level 41.09

See More

52-Week High 61.61
Fibonacci 61.8% 46.58
Last Price 42.93
Fibonacci 50% 41.94
Fibonacci 38.2% 37.29
52-Week Low 22.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar